Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma

Bone Marrow Transplantation

Volumn 23, Issue 2, 1999, Pages 107-110

  Grigg, A ^a   Bardy, P ^a   Byron, K ^a   Seymour, J F ^a   Szer, J ^a  

^a NONE

Author keywords

Fludarabine; Mini allografting; Non myeloablative therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHIMERA; CLINICAL ARTICLE; CONDITIONING; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RELAPSE; REMISSION; SPLENOMEGALY; STEM CELL TRANSPLANTATION;

EID: 0032941295     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701540     Document Type: Article

References (10)

1. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
2. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukaemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 11: 3377-3383.
3. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
4. Estey E, Thall P, Andreeff M et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671-678.
5. Seymour JF, Grigg A, Szer J, Fox RM. Fludarabine, cisplatin and ara-C: an active regimen in patients with anthracycline-refractory intermediate-grade non-Hodgkin's lymphoma. Blood 1995; 86 (Suppl. 1): 55a (Abstr 209).
6. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
7. Boerwinkle E, Xiong W, Fourest E, Chan L. Rapid typing of tandemly repeated hypervariable loci by the polymerase chain reaction: application to the apolipoprotein B 3′ hypervariable region. Proc Natl Acad Sci USA 1989; 86: 212-216.
8. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
9. Bensinger WI, Clift RA, Anasetti C et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells 1996; 14: 90-105.
10. Rondón G, Giralt S, Huh Y et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669-672.